Pharmaceutical companies Biogen, in Cambridge, Massachusetts ... Dreambooth can produce realistic images based on just a few pictures of a specific subject. The technique is based on an existing ...

All news and actualities about aerial, marine, rail and terrestrial transportation of people and merchandise. We also discuss public transportation. On January 23, 2025, Farizon successfully held ...

Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

Sage Therapeutics has rejected a buyout bid from partner Biogen and launched a review of strategic alternatives. Sage on Monday said its board determined that Biogen's $7.22-a-share proposal ...

The Cambridge, Massachusetts-based biotech added that its board of directors, along with its independent financial and legal advisors, will evaluate Biogen’s (NASDAQ:BIIB) bid and decide on the ...

Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

This evening and early part of the night will be dry with clear skies. It will turn cloudier after midnight with spells of rain pushing in from the north-west, which will be heavy in places ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. However, the company's board of directors ...

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience partner. The lawsuit is sealed in Delaware’s Court of Chancery ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target of $138.00. The company’s shares closed yesterday ...

Sage Therapeutics (NASDAQ:SAGE) is reportedly suing Biogen (NASDAQ:BIIB) over enforcement of a standstill agreement in the wake of an unsolicited takeover bid valued at around $469M. The full ...

SPINRAZA. Biogen Inc, Cambridge, MA. Finkle et al. Cure SMA 2024. “Final Safety and Efficacy Data From the SHINE Study in Participants With Infantile-Onset and Later-Onset SMA.” ...